National
Will Senate address bullying in education reform?
Franken, Casey may offer pro-LGBT amendments
Sen. Bob Casey (D-Pa.) (Blade photo by Michael Key)
A Senate committee markup this week could present an opportunity to include LGBT anti-bullying measures as part of larger education reform legislation — although whether the panel will act remains unclear.
Starting Wednesday, the Senate Health, Education, Labor & Pensions Committee will consider amendments and vote on legislation to reauthorize the Elementary & Secondary Education Act, an extensive law that helps fund primary and secondary schools throughout the country.
President Obama has identified reauthorization of the law, which was last updated in 2001 during the Bush administration with the No Child Left Behind Act, as among his priorities for this year. At the onset of the 112th Congress, passage of education reform — and possibly LGBT-inclusive legislation — was seen as an area where where a Republican-controlled House and a Democratic-controlled Senate could come to an agreement to take action.
LGBT advocates had been pushing for the inclusion of two-LGBT bills as part of education reform — the Student Non-Discriminination Act and the Safe Schools Improvement Act.
The Student Non-Discrimination Act, or SNDA, is sponsored by Sen. Al Franken (D-Minn.) in the Senate. It establishes sexual orientation and gender identity in schools as protected classes. The bill prohibits school activities receiving federal financial assistance from discriminating against LGBT students. Discrimination also includes harassment of a student.
The Safe Schools Improvement Act, or SSIA, is sponsored by Sen. Bob Casey (D-Pa.) in the Senate. It would require schools receiving federal funds to adopt codes of conduct that prohibit bullying and harassment, including on the basis of sexual orientation and gender identity. The legislation would also require states to report data on bullying and harassment to the Department of Education.
Whether Franken or Casey will offer amendments based on these bills during the Senate HELP committee’s markup remains to be seen. The offices of both senators were non-committal on plans to offer them during the markup process.
Alexandra Fetissoff, a Franken spokesperson, said the senator is committed to SNDA but has yet to make a decision on the best opportunity to introduce the legislation before the Senate.
“He’s currently weighing his options — offering the bill to the committee or as an amendment when ESEA comes to the floor,” Fetissoff said. “He’s hopeful that SNDA will pass as he firmly believes it’s the right thing to do and he believes his colleagues will come to realize that.”
Should Franken offer the amendment during the committee markup process, he should have no problem getting the measure through the committee. All 12 Democrats on the panel are co-sponsors of the bill, which should give it majority support for passage. The legislation has no Republican co-sponsors.
April Mellody, a Casey spokesperson, similarly said plans aren’t yet settled on whether or not her boss will introduce SSIA as an amendment during the markup. She said Casey is “currently working with the other members regarding the amendment process.”
But Mellody said language in the chairman’s mark for the base bill already addresses bullying. Under a provision called Successful, Safe and Healthy Schools, schools receiving grants under the program must have student conduct policies that prohibit bullying and harassment, a key principle of SSIA.
Mellody said Casey is “pleased” with the provision, but would like to see language with enumerated categories that is explicitly LGBT-inclusive.
“Sen. Casey believes those policies should also include specific characteristics, including sexual orientation and gender identity, among others, as protected categories,” Mellody said.
Should Casey decide to offer SSIA as an amendment during committee, he could have more difficulty than Franken would if he offered up SNDA. Of the 12 Democrats on the panel, 10 are co-sponsors. Sens. Michael Bennett (D-Colo.) and Jeff Bingaman (D-N.M.) aren’t co-sponsors of the bill.
On the Republican side, Sen. Mark Kirk (R-Ill.) is an original co-sponsor of the bill, bringing the total number of co-sponsors to 11. That could be short of the 12 votes needed for passage if the bill comes up during committee.
However, given that Bingaman and Bennett are co-sponsors for SNDA and voted in favor of “Don’t Ask, Don’t Tell” repeal last year, their support for SSIA is likely should the measure come up in committee.
Michael Cole-Schwartz, spokesperson for the Human Rights Campaign, said plans remain “up in the air” over whether SNDA or SSIA will come up during the committee markup.
“We don’t know how this is going to turn out,” Cole-Schwartz said. “Certainly, we’ve been advocating on the Hill very strenuously for both of these provisions into the reauthorization, working with our allies in Sen. Casey’s office and Sen. Franken’s office.”
Cole-Schwartz said “it’s poignant” the markup would take place at the same time that the bullying of gay students who committed suicide has been in the news and around the same time as Spirit Day. On Thursday, millions of Americans are expected to wear purple as a sign of support for LGBT youth and to speak out against bullying.
“I think the Senate has a great opportunity to take advantage of this moment that we’re in and really do something to improve the lives of these young people,” Cole-Schwartz said.
If Franken and Casey were to move forward with these amendments, they would be doing so without explicit backing from the Obama administration. President Obama has yet to endorse either SNDA or SSIA.
Shin Inouye, a White House spokesperson, said the administration continues to support the goals of the bills, but stopped short of offering explicit support for them.
“We support the goals of both of these efforts,” Inouye said. “As the Elementary and Secondary Education Act is being considered, we look forward to working with Congress to ensure that all students are safe and healthy and can learn in environments free from discrimination, bullying and harassment.”
UPDATE: An LGBT rights advocate, who spoke on condition of anonymity, said Senate HELP Committee Chair Tom Harkin (D-Iowa) is the “obstacle” in including SNDA and SSIA in the education reform markup.
The advocate said Harkin isn’t opposed to the bills, but wants “a clean markup process” so education reform “can sail through” without opposition. Harkin co-sponsors both SSIA and SNDA.
“They want clean markup processes so that their bills can go through without opposition,” the advocate said. “So there’s kind of a dance and negotiation going on.”
The anonymous advocate said Franken and Casey are “really trying to negotiate their way” to include their bills in the committee markup, but no decision has yet made on whether they’ll offer those amendments.
ADDITIONAL UPDATE: The committee markup process has been halted after objections from Republican senators. In committee, Harkin said he expects the panel to reconvene either in the evening on Wednesday or early Thursday.
A Harkin spokesperson, also speaking anonymously, responded to the assertion that the senator is an “obstacle” in including SSIA and SNDA in the committee markup by saying Harkin has “long supported efforts to ensure that all children feel safe and secure in our schools.”
“He believes that no student should be forced to endure harassment, discrimination, violence, bullying or intimidation for any reason, including their sexual orientation or gender identity,” the spokesperson said. “Chairman Harkin is an original co-sponsor of the Student Non-Discrimination Act and is committed to working with Sen. Franken, author of SNDA, and Sen. Casey, author of the Safe Schools Improvement Act, to ensure all students are given the opportunity to succeed free from harassment or discrimination.”
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
The White House
EXCLUSIVE: Democracy Forward files FOIA lawsuit after HHS deadnames Rachel Levine
Trans former assistant health secretary’s name changed on official portrait
Democracy Forward, a national legal organization that works to advance democracy and social progress through litigation, policy and public education, and regulatory engagement, filed a lawsuit Friday in federal court seeking to compel the U.S. Department of Health and Human Services to release information related to the alteration of former Assistant Secretary for Health Adm. Rachel Levine’s official portrait caption.
The lawsuit comes in response to the slow pace of HHS’s handling of multiple Freedom of Information Act requests — requests that federal law requires agencies to respond to within 20 working days. While responses can take longer due to backlogs, high request volumes, or the need for extensive searches or consultations, Democracy Forward says HHS has failed to provide any substantive response.
Democracy Forward’s four unanswered FOIA requests, and the subsequent lawsuit against HHS, come days after someone in the Trump-Vance administration changed Levine’s official portrait in the Hubert H. Humphrey Building to display her deadname — the name she used before transitioning and has not used since 2011.
According to Democracy Forward, HHS “refused to release any records related to its morally wrong and offensive effort to alter former Assistant Secretary for Health Admiral Rachel Levine’s official portrait caption.” Levine was the highest-ranking openly transgender government official in U.S. history and served as assistant secretary for health and as an admiral in the U.S. Public Health Service Commissioned Corps from 2021 to 2025.
Democracy Forward President Skye Perryman spoke about the need to hold the Trump-Vance administration accountable for every official action, especially those that harm some of the most targeted Americans, including trans people.
“The question every American should be asking remains: what is the Trump-Vance administration hiding? For an administration that touts its anti-transgender animus and behavior so publicly, its stonewalling and silence when it comes to the people’s right to see public records about who was behind this decision is deafening,” Perryman said.
“The government’s obligation of transparency doesn’t disappear because the information sought relates to a trailblazing former federal official who is transgender. It’s not complicated — the public is entitled to know who is making decisions — especially decisions that seek to alter facts and reality, erase the identity of a person, and affect the nation’s commitment to civil rights and human dignity.”
“HHS’s refusal to respond to these lawful requests raises more serious concerns about transparency and accountability,” Perryman added. “The public has every right to demand answers — to know who is behind this hateful act — and we are going to court to get them.”
The lawsuit also raises questions about whether the alteration violated federal accuracy and privacy requirements governing Levine’s name, and whether the agency improperly classified the change as an “excepted activity” during a lapse in appropriations. By failing to make any determination or produce any records, Democracy Forward argues, HHS has violated its obligations under federal law.
The case, Democracy Forward Foundation v. U.S. Department of Health and Human Services, was filed in the U.S. District Court for the District of Columbia. The legal team includes Anisha Hindocha, Daniel McGrath, and Robin Thurston.
The Washington Blade reached out to HHS, but has not received any comment.
The lawsuit and four FOIA requests are below:
Long-awaited ‘Pillion’ surpasses the sexy buzz
Trump’s ‘American people derangement syndrome’
Reasons to be optimistic about 2026
Using movement to boost your mental health during holidays
Protecting the trans community is not optional for elected allies and candidates
Reasons to be optimistic about 2026
America is going in the wrong direction for intersex children
Rush reopens after renewing suspended liquor license
Long-awaited ‘Pillion’ surpasses the sexy buzz
